All Articles tagged maximum fair price
- Brief Report
November 27, 2024 EDT This brief report presents a model that evaluates how increased out-of-pocket costs for the anticoagulants apixaban (Eliquis) and rivaroxaban (Xarelto) could impact patients financially and clinically.